Focused On-demand Library for Mitochondrial ribonuclease P catalytic subunit

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O15091

UPID:
MRPP3_HUMAN

ALTERNATIVE NAMES:
Mitochondrial ribonuclease P protein 3; Protein only RNase P catalytic subunit

ALTERNATIVE UPACC:
O15091; B4DXD9; B4E0S8; B4E211; C4AM93; D3DS99; D3DSA1; Q86SZ4; Q86YB5; Q8N5L5

BACKGROUND:
Mitochondrial ribonuclease P catalytic subunit, alternatively named Mitochondrial ribonuclease P protein 3, is crucial for mitochondrial RNA maturation. It functions within the mitochondrial ribonuclease P complex to precisely cleave the 5'-ends of tRNA molecules, facilitating their proper function in protein synthesis. This enzymatic activity is essential for maintaining mitochondrial health and function, highlighting the protein's significance in cellular energy metabolism.

THERAPEUTIC SIGNIFICANCE:
Mutations in the gene encoding the Mitochondrial ribonuclease P catalytic subunit are implicated in Combined oxidative phosphorylation deficiency 54, characterized by diverse clinical features such as developmental delays and leukoencephalopathy. Exploring the molecular mechanisms of this protein offers promising avenues for developing targeted therapies for mitochondrial diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.